

**R. Wilson** has received fees for lecturing about ciprofloxacin D81 and sitting on advisory boards concerning the compound.

**T. Welte** has received fees for lectures from Bayer, Gilead and Novartis. The author is a member of the international advisory boards of Bayer and Gilead. He has received research grants from Bayer and Novartis.

**E. Polverino** has been contracted sporadically as a consultant on “bronchiectasis disease” by Bayer and was involved in the present clinical trial as a collaborating investigator.

**A. De Soyza** has received travel to the ERS congress that was funded by GSK, Chiesi and Boehringer-Ingelheim; has received support to attend the British Thoracic Society Winter meeting from Boehringer Ingelheim; has also received speakers fees or advisory fees from Novartis, Bayer, Boehringer Ingelhiem, Astra Zeneca, GSK, Almirall, Pfizer and Forest laboratories; and has received financial support from Forest laboratories for an investigator led grant.

**A. O'Donnell** has received fees from Bayer for speaking at and organising an educational symposium and for attending consulting panels, and was the principal investigator at Georgetown University for the present study.

**J. Adler** is an employee of Bayer Healthcare Pharmaceuticals, and holds stock and unvested stock in Bayer.

**P. Reimnitz** is an employee of Bayer Pharma AG.

**B. Hampel** is an employee of Bayer Pharma AG and holds stock in Bayer.